How to treat cancer with SIRP alpha FC fusion in combination with immune checkpoint inhibitors

摘要

comprising administering to the individual (a) a polypeptide comprising a SIRPα D1 domain variant and an Fc domain variant, and (b) an anti-cancer antibody (eg , an anti-PD1 antibody, an anti-HER2 antibody, or an anti-CD20 antibody). Cancer (e.g.,Non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (HNSCC), HER2-positive gastroesophageal junction (GEJ) cancer, novel or transformedA method of treating diffuse large B-cell lymphoma (DLBCL), or indolent lymphoma) is provided. Related kit pharmaceutical compositions are also provided.